Equities research analysts expect that DENTSPLY SIRONA Inc. (NASDAQ:XRAY) will report $1.00 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for DENTSPLY SIRONA’s earnings. The lowest sales estimate is $986.20 million and the highest is $1.02 billion. DENTSPLY SIRONA posted sales of $1.02 billion during the same quarter last year, which suggests a negative year over year growth rate of 2%. The company is expected to announce its next earnings report on Friday, August 4th.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full year sales of $1.00 billion for the current fiscal year, with estimates ranging from $4.00 billion to $4.07 billion. For the next year, analysts forecast that the company will post sales of $4.24 billion per share, with estimates ranging from $4.16 billion to $4.30 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, May 9th. The medical instruments supplier reported $0.49 EPS for the quarter, missing the consensus estimate of $0.50 by $0.01. The company had revenue of $900.50 million for the quarter, compared to analyst estimates of $916.55 million. DENTSPLY SIRONA had a return on equity of 7.37% and a net margin of 9.42%. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period last year, the business earned $0.69 EPS.

A number of research analysts have recently weighed in on XRAY shares. BidaskClub cut shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Saturday, June 10th. Cleveland Research raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. Goldman Sachs Group, Inc. (The) cut shares of DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $60.00 to $55.00 in a research note on Tuesday, May 23rd. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Thursday, March 30th. Finally, Barrington Research cut shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company. DENTSPLY SIRONA has an average rating of “Buy” and a consensus target price of $66.44.

In related news, CEO James G. Mosch sold 50,600 shares of DENTSPLY SIRONA stock in a transaction on Monday, April 24th. The shares were sold at an average price of $63.49, for a total transaction of $3,212,594.00. Following the transaction, the chief executive officer now owns 105,083 shares in the company, valued at approximately $6,671,719.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher T. Clark sold 89,700 shares of DENTSPLY SIRONA stock in a transaction on Friday, April 7th. The shares were sold at an average price of $62.67, for a total transaction of $5,621,499.00. Following the transaction, the chief executive officer now owns 112,067 shares in the company, valued at approximately $7,023,238.89. The disclosure for this sale can be found here. 1.99% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of XRAY. Sandhill Capital Partners LLC acquired a new position in DENTSPLY SIRONA during the fourth quarter valued at $15,928,000. Foresters Investment Management Company Inc. raised its position in DENTSPLY SIRONA by 0.3% in the fourth quarter. Foresters Investment Management Company Inc. now owns 79,000 shares of the medical instruments supplier’s stock valued at $4,680,000 after buying an additional 200 shares during the last quarter. Alyeska Investment Group L.P. raised its position in DENTSPLY SIRONA by 59.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,015,507 shares of the medical instruments supplier’s stock valued at $58,625,000 after buying an additional 380,007 shares during the last quarter. LaFleur & Godfrey LLC acquired a new position in DENTSPLY SIRONA during the first quarter valued at $3,323,000. Finally, Farmers & Merchants Investments Inc. raised its position in DENTSPLY SIRONA by 3.6% in the first quarter. Farmers & Merchants Investments Inc. now owns 94,521 shares of the medical instruments supplier’s stock valued at $5,902,000 after buying an additional 3,300 shares during the last quarter. Institutional investors and hedge funds own 95.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Financial Market News and is owned by of Financial Market News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.financial-market-news.com/2017/06/17/dentsply-sirona-inc-xray-expected-to-post-quarterly-sales-of-1-00-billion.html.

Shares of DENTSPLY SIRONA (NASDAQ XRAY) traded up 0.62% during mid-day trading on Friday, hitting $63.70. 1,700,481 shares of the stock traded hands. The firm’s 50-day moving average is $63.20 and its 200-day moving average is $61.05. DENTSPLY SIRONA has a 52 week low of $55.00 and a 52 week high of $65.83. The stock has a market cap of $14.60 billion, a price-to-earnings ratio of 40.99 and a beta of 1.25.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.